The effectiveness of the use of ethylmethylhydroxypyridine of succinate in the restoration treatment of patients who have undergone ischemic stroke

Authors:
M.V. ZHURAVLEVA^1,2, A.B. PROKOFIEV^1,2, V.V. ARKHIPOV¹, S.Yu. SEREBROVA^1,2, G.I. GORODETSKAYA^1,2, O.A. DEMIDOVA¹

¹Federal State Budgetary Institution "Scientific Center for Expertise of Medical Products" of the Ministry of Health of the Russian Federation, Moscow, Russia;
²Federal State Autonomous Educational Institution of Higher Education "I.M. Sechenov First Moscow State Medical University" of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY 2020, Vol. 120, No. 3, pp. 87-91

Abstract:
An analysis of the clinical efficacy and safety of ethylmethylhydroxypyridine succinate (Mexidol) as part of a rehabilitation program for patients who have suffered ischemic stroke (IS) was conducted. A course of treatment with the drug was shown to improve neurological function recovery, regression of neurological deficits and cognitive impairments, including improved memory, reduced asthenic symptoms, increased social adaptation, and improved psychoemotional well-being, reduced spasticity, increased motor and speech activity, and praxis, as well as significant elimination of neglect syndrome. Patients who have suffered IS showed decreased blood levels of total cholesterol and low-density B-lipoproteins, and a reduction in the severity of hypercoagulability. The results of the studies convincingly demonstrated the feasibility of using ethylmethylhydroxypyridine succinate (Mexidol) at all stages of rehabilitation treatment for patients who have suffered IS. Key words: ethylmethylhydroxypyridine succinate, Mexidol, rehabilitation, recovery, stroke.